Found: 141
Select item for more details and to access through your institution.
Improving an electronic system for measuring PROs in routine oncology practice.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 3, p. 539, doi. 10.1007/s00280-014-2380-5
- By:
- Publication type:
- Article
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 883, doi. 10.1007/s00280-013-2079-z
- By:
- Publication type:
- Article
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 3, p. 763, doi. 10.1007/s00280-011-1759-9
- By:
- Publication type:
- Article
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 431, doi. 10.1007/s00280-010-1328-7
- By:
- Publication type:
- Article
Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Bone-targeting agents in prostate cancer.
- Published in:
- Cancer & Metastasis Reviews, 2014, v. 33, n. 2/3, p. 619, doi. 10.1007/s10555-013-9480-2
- By:
- Publication type:
- Article
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).
- Published in:
- Journal of Patient-Reported Outcomes, 2018, v. 2, n. 1, p. N.PAG, doi. 10.1186/s41687-018-0054-5
- By:
- Publication type:
- Article
Association of pretreatment neutrophil-to-lymphocyte ratio ( NLR) and overall survival ( OS) in patients with metastatic castration-resistant prostate cancer ( mCRPC) treated with first-line docetaxel.
- Published in:
- BJU International, 2014, v. 114, n. 6b, p. E11, doi. 10.1111/bju.12531
- By:
- Publication type:
- Article
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2012, v. 110, n. 11b, p. E575, doi. 10.1111/j.1464-410X.2012.11286.x
- By:
- Publication type:
- Article
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
- Published in:
- BJU International, 2012, v. 109, n. 1, p. 32, doi. 10.1111/j.1464-410X.2011.10422.x
- By:
- Publication type:
- Article
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial.
- Published in:
- International Journal of Cancer, 2015, v. 136, n. 8, p. 1856, doi. 10.1002/ijc.29212
- By:
- Publication type:
- Article
Lateralization and Decreased Neck-Shaft Angle Reduces Scapular Notching and Heterotopic Ossification.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study.
- Published in:
- Trials, 2012, v. 13, n. 1, p. 237, doi. 10.1186/1745-6215-13-237
- By:
- Publication type:
- Article
Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2010, v. 9, n. 5, p. 297, doi. 10.3816/CCC.2010.n.043
- By:
- Publication type:
- Article
A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters.
- Published in:
- Cancer Gene Therapy, 2001, v. 8, n. 12, p. 927, doi. 10.1038/sj.cgt.7700385
- By:
- Publication type:
- Article
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
- Published in:
- Prostate, 2024, v. 84, n. 10, p. 909, doi. 10.1002/pros.24707
- By:
- Publication type:
- Article
Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805.
- Published in:
- Prostate, 2022, v. 82, n. 12, p. 1176, doi. 10.1002/pros.24369
- By:
- Publication type:
- Article
What are survivorship care plans failing to tell men after prostate cancer treatment?
- Published in:
- Prostate, 2021, v. 81, n. 7, p. 398, doi. 10.1002/pros.24116
- By:
- Publication type:
- Article
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial.
- Published in:
- Prostate, 2021, v. 81, n. 6, p. 326, doi. 10.1002/pros.24110
- By:
- Publication type:
- Article
Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
- Published in:
- Prostate, 2020, v. 80, n. 16, p. 1429, doi. 10.1002/pros.24074
- By:
- Publication type:
- Article
Genomic and clinical characterization of pulmonary‐only metastatic prostate cancer: A unique molecular subtype.
- Published in:
- Prostate, 2019, v. 79, n. 13, p. 1572, doi. 10.1002/pros.23881
- By:
- Publication type:
- Article
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302.
- Published in:
- Prostate, 2019, v. 79, n. 8, p. 929, doi. 10.1002/pros.23798
- By:
- Publication type:
- Article
Risk factors for metastatic prostate cancer: A sentinel event case series.
- Published in:
- Prostate, 2017, v. 77, n. 13, p. 1366, doi. 10.1002/pros.23396
- By:
- Publication type:
- Article
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
- Published in:
- Prostate, 2016, v. 76, n. 13, p. 1218, doi. 10.1002/pros.23209
- By:
- Publication type:
- Article
Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
- Published in:
- Prostate, 2016, v. 76, n. 5, p. 512, doi. 10.1002/pros.23141
- By:
- Publication type:
- Article
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
- Published in:
- Prostate, 2015, v. 75, n. 14, p. 1518, doi. 10.1002/pros.23024
- By:
- Publication type:
- Article
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
- Published in:
- Prostate, 2014, v. 74, n. 15, p. 1560, doi. 10.1002/pros.22874
- By:
- Publication type:
- Article
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
- Published in:
- Prostate, 2014, v. 74, n. 4, p. 433, doi. 10.1002/pros.22765
- By:
- Publication type:
- Article
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
- Published in:
- Prostate, 2012, v. 72, n. 5, p. 487, doi. 10.1002/pros.21449
- By:
- Publication type:
- Article
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: Clinical factors associated with PSA response and disease progression.
- Published in:
- Prostate, 2012, v. 72, n. 4, p. 461, doi. 10.1002/pros.21447
- By:
- Publication type:
- Article
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation.
- Published in:
- Prostate, 2011, v. 71, n. 15, p. 1608, doi. 10.1002/pros.21377
- By:
- Publication type:
- Article
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
- Published in:
- Prostate, 2011, v. 71, n. 4, p. 333, doi. 10.1002/pros.21247
- By:
- Publication type:
- Article
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
- Published in:
- Prostate, 2007, v. 67, n. 10, p. 1099, doi. 10.1002/pros.20587
- By:
- Publication type:
- Article
Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice.
- Published in:
- Psycho-Oncology, 2013, v. 22, n. 4, p. 895, doi. 10.1002/pon.3087
- By:
- Publication type:
- Article
A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer.
- Published in:
- Molecular Therapy, 2006, v. 14, n. 1, p. 107, doi. 10.1016/j.ymthe.2006.02.011
- By:
- Publication type:
- Article
Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib.
- Published in:
- Oncologist, 2014, v. 19, n. 1, p. 51, doi. 10.1634/theoncologist.2012-0335
- By:
- Publication type:
- Article
Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Oncologist, 2013, v. 18, n. 2, p. 163, doi. 10.1634/theoncologist.2012-314
- By:
- Publication type:
- Article
Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram.
- Published in:
- Oncologist, 2012, v. 17, n. 12, p. 1508, doi. 10.1634/theoncologist.2012-0125
- By:
- Publication type:
- Article
DOCETAXEL IN ANDROGEN-INDEPENDENT PROSTATE CANCER: AN UPDATE.
- Published in:
- BJU International, 2004, v. 94, n. 9, p. 1209, doi. 10.1111/j.1464-410X.2004.05216.x
- By:
- Publication type:
- Article
Long-term effects of androgen deprivation therapy in prostate cancer patients.
- Published in:
- Clinical Endocrinology, 2002, v. 56, n. 6, p. 779, doi. 10.1046/j.1365-2265.2002.01551.x
- By:
- Publication type:
- Article
It's who you know: patient-sharing, quality, and costs of cancer survivorship care.
- Published in:
- Journal of Cancer Survivorship, 2014, v. 8, n. 2, p. 156, doi. 10.1007/s11764-014-0349-3
- By:
- Publication type:
- Article
Preventive care in prostate cancer patients: following diagnosis and for five-year survivors.
- Published in:
- Journal of Cancer Survivorship, 2011, v. 5, n. 3, p. 283, doi. 10.1007/s11764-011-0181-y
- By:
- Publication type:
- Article
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Identification and characterization of circulating prostate carcinoma cells.
- Published in:
- 2000
- By:
- Publication type:
- journal article
The experience with suramin in advanced prostate cancer.
- Published in:
- Cancer (0008543X), 1995, v. 75, n. S7, p. 1927, doi. 10.1002/1097-0142(19950401)75:7+<1927::AID-CNCR2820751628>3.0.CO;2-A
- By:
- Publication type:
- Article
Gene therapy for human prostate cancer. Translational research in the hormone refractory dunning prostate cancer model.
- Published in:
- Cancer (0008543X), 1995, v. 75, n. S7, p. 2013, doi. 10.1002/1097-0142(19950401)75:7+<2013::AID-CNCR2820751643>3.0.CO;2-P
- By:
- Publication type:
- Article
Erratum: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
- Published in:
- 2009
- By:
- Publication type:
- Correction Notice
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
- Published in:
- Nature Medicine, 2009, v. 15, n. 5, p. 559, doi. 10.1038/nm.1944
- By:
- Publication type:
- Article